Evidence map›Paper›PMID 31742674›Full record

ArticleCancer2020

Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends.

Chad Tang, Karen E Hoffman, Pamela K Allen, Molly Gabel, David Schreiber, Seungtaek Choi, Brian F Chapin, Quynh-Nhu Nguyen, John W Davis, Paul Corn and 15 more

Abstract read
In one paragraph

Article in Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Disparities With Systemic Therapies for Black Men Having Advanced Prostate Cancer: Where Do We Stand?Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Tackling Health Care Disparities: How to Build a Sarcoidosis Center.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2022
    Review
  11. Article
  12. Article
  13. Influence of Geography on Prostate Cancer Treatment.International journal of radiation oncology, biology, physics · 2021
    Article
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Chad TangDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-5915-1327
Karen E HoffmanDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Pamela K AllenDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Molly GabelDepartment of Radiation Oncology, Summit Medical Group, Summit, New Jersey.
David SchreiberDepartment of Radiation Oncology, Summit Medical Group, Summit, New Jersey.
Seungtaek ChoiDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Brian F ChapinDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Quynh-Nhu NguyenDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
John W DavisDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Paul CornDepartment of genitourinary medical oncology, The University of Texas MD Anderson cancer center, Houston, Texas.
Christopher LogothetisDepartment of genitourinary medical oncology, The University of Texas MD Anderson cancer center, Houston, Texas.
John WardDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Steven J FrankDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Neema NavaiDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Sean E McGuireDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Mitchell AnscherDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Louis PistersDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Curtis A PettawayDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Rachit KumarBanner MD Anderson Cancer Center, Mesa, Arizona.
Patrick LinsonScripps MD Anderson Cancer Center, San Diego, California.
Prabhakar TripuraneniScripps MD Anderson Cancer Center, San Diego, California.
Jeffrey J TomaszewskiDepartment of Urology, MD Anderson Center at Cooper, Camden, New Jersey.
Ashish B PatelMD Anderson Cancer Center at Cooper, Camden, New Jersey.
Mark AugspurgerBaptist MD Anderson Cancer Center, Jacksonville, Florida.
Deborah A KubanDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

backgroundThe purpose of this study was to assess treatment choices among men with prostate cancer who presented at The University of Texas MD Anderson Cancer Center multidisciplinary (MultiD) clinic compared with nationwide trends.

methodsIn total, 4451 men with prostate cancer who presented at the MultiD clinic from 2004 to 2016 were analyzed. To assess nationwide trends, the authors analyzed 392,710 men with prostate cancer who were diagnosed between 2004 and 2015 from the Surveillance, Epidemiology, and End Results (SEER) database. The primary endpoint was treatment choice as a function of pretreatment demographics.

resultsUnivariate analyses revealed similar treatment trends in the MultiD and SEER cohorts. The use of procedural forms of definitive therapy decreased with age, including brachytherapy and prostatectomy (all P < .05). Later year of diagnosis/clinic visit was associated with decreased use of definitive treatments, whereas higher risk grouping was associated with increased use (all P < .001). Patients with low-risk disease treated at the MultiD clinic were more likely to receive nondefinitive therapy than patients in SEER, whereas the opposite trend was observed for patients with high-risk disease, with a substantial portion of high-risk patients in SEER not receiving definitive therapy. In the MultiD clinic, African American men with intermediate-risk and high-risk disease were more likely to receive definitive therapy than white men, but for SEER the opposite was true.

conclusionsPresentation at a MultiD clinic facilitates the appropriate disposition of patients with low-risk disease to nondefinitive strategies of patients with high-risk disease to definitive treatment, and it may obviate the influence of race.

Indexed as

AgedBlack or African AmericanBrachytherapyHumansMaleMiddle AgedPatient SelectionProstatectomyProstate-Specific AntigenProstatic NeoplasmsSEER ProgramUnited StatesWhite PeopleProstate-Specific Antigenand End Results (SEER)Epidemiologymultidisciplinary clinicprostate cancerSurveillancetreatment access

Identifiers

PMID31742674
PMCPMC6980273

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.